ReviewCurrent rheumatology reports2022
A Spotlight on Drug-Induced Vasculitis.
Review in Current rheumatology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Cocaine-Levamisole-Associated Vasculopathy Mimicking ANCA-Associated Vasculitis and Presenting With Pulmonary-Renal Syndrome Requiring VV-ECMO Support.The American journal of case reports · 2026Article
- A visual guide for emergency radiologists navigating the complexity of abdominal vasculitis: part 1 - true vasculitis.Emergency radiology · 2026Review
- Case Report: Fluoxetine-induced leucocytoclastic vasculitis.Frontiers in psychiatry · 2026Article
- A new category for understanding the mechanisms of drug-induced kidney injury.Renal failure · 2025Review
- Elevated Serum Protease 3 Antineutrophil Cytoplasmic Antibody in Mesalazine-Intolerant Ulcerative Colitis: A Potential Diagnostic Biomarker.Journal of clinical medicine · 2025Article
- Cocaine- and Levamisole-Induced Vasculitis (CLIV).Cureus · 2025Review
- Comprehensive Management of Cocaine-Induced Midline Destructive Lesions: A Young-IfOS Consensus.Journal of personalized medicine · 2025Article
- New Diagnosis of Granulomatosis With Polyangiitis Presenting With Oral Ulcerations, Ileitis, and Hematochezia.ACG case reports journal · 2025Article
- Haptenization as the missing link between vasculitis and myeloperoxidase.The Journal of clinical investigation · 2025Article
- Vancomycin- induced leukocytoclastic vasculitis in a patient with end-stage renal disease: a case report and literature review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Review
- Rare skin adverse reactions induced by osimertinib: a case report and literature review.Frontiers in oncology · 2025Article
- Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography revealed the course of granulocyte-colony stimulating factor-associated aortitis: A case report.Radiology case reports · 2024Article
- Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome.International journal of molecular sciences · 2024Review
- Pulmonary pathology in vasculitis.Pathologica · 2024Review
- Minocycline-induced vasculitis.Clinical rheumatology · 2024Article
- Article
- Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement.BMC nephrology · 2023Article
- Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.BMJ case reports · 2023Article
- Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.International journal of molecular sciences · 2023Review
- Cardiac tamponade, a rare complication of gastric cardia cancer resection after neoadjuvant chemotherapy combined with immunotherapy: a case report and literature review.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDrug-induced vasculitis (DIV) is a rare form of vasculitis related to the use of various drugs. DIV primarily affects small to medium size vessels, but it can potentially involve vessels of any size. Differentiating between primary systemic vasculitis and DIV can be challenging; however, it is crucial, so that the offending agent can be discontinued promptly. RECENT
findingsThe clinical phenotype of DIV is protean and depends on the size of the affected vessels. It ranges from arthralgias, to an isolated cutaneous rash, to severe single or multi-organ involvement. While withdrawal of the offending drug is the most important step in management, a significant number of patients require immunosuppressive therapy for varying periods of time. DIV can affect any vascular bed size, leading to protean vasculitic syndromes. Increased awareness among general practitioners, specialty, and subspecialty physicians is crucial for early recognition, and withdrawal of drug for better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.